Cargando…

Renal angiotensin I-converting enzyme-deficient mice are protected against aristolochic acid nephropathy

The renal renin-angiotensin system (RAS) is involved in the development of chronic kidney disease. Here, we investigated whether mice with reduced renal angiotensin I-converting enzyme (ACE(−/−)) are protected against aristolochic acid nephropathy (AAN). To further elucidate potential molecular mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juretzko, Annett, Steinbach, Antje, Witte, Jeannine, Hannemann, Anke, Miehe, Bärbel, Siegerist, Florian, Wolke, Carmen, Stracke, Sylvia, Rettig, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Organ Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908662/ https://www.ncbi.nlm.nih.gov/pubmed/36520238 http://dx.doi.org/10.1007/s00424-022-02779-4

Ejemplares similares

Update of aristolochic acid nephropathy in Korea
por: Ban, Tae Hyun, et al.
Publicado: (2018)

Overview of aristolochic acid nephropathy: an update
por: Zhou, Qingqing, et al.
Publicado: (2023)

U-shaped association between central body fat and the urinary albumin-to-creatinine ratio and microalbuminuria
por: Dittmann, Kathleen, et al.
Publicado: (2013)

Angiotensin converting enzyme gene polymorphism in type II diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2009)

Angiotensin converting enzyme gene polymorphism in type 2 diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2010)

An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature
por: Jadot, Inès, et al.
Publicado: (2017)

A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy
por: Pathak, Jahnavi V., et al.
Publicado: (2015)

Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
por: Aggarwal, Neerja, et al.
Publicado: (2017)

A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy
por: Gilbert, Akankwasa, et al.
Publicado: (2018)

Arterial Stiffness in Balkan Endemic Nephropathy, an Environmental Form of Aristolochic Acid Nephropathy
por: Premužić, Vedran, et al.
Publicado: (2018)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy
por: Yi, Joo-Hark, et al.
Publicado: (2018)

«Suspects» in Etiology of Endemic Nephropathy: Aristolochic Acid versus Mycotoxins
por: Pepeljnjak, Stjepan, et al.
Publicado: (2010)

Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy
por: Nomura, Haru, et al.
Publicado: (2022)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Dual deficiency of angiotensin‐converting enzyme‐2 and Mas receptor enhances angiotensin II‐induced hypertension and hypertensive nephropathy
por: Ni, Jun, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Pharmacokinetics of p-Aminohippuric Acid and Inulin in Rabbits with Aristolochic Acid Nephropathy
por: Tseng, Chiao-Shih, et al.
Publicado: (2011)

Smad7 protects against chronic aristolochic acid nephropathy in mice
por: Dai, Xiao-Yu, et al.
Publicado: (2015)

Protective Effects of Melatonin Against Aristolochic Acid-Induced Nephropathy in Mice
por: Kim, Jung-Yeon, et al.
Publicado: (2019)

Growing risk of aristolochic acid nephropathy in the era of COVID-19 – Correspondence
por: Das, Tuyelee, et al.
Publicado: (2022)

Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice
por: Nadarajah, Renisha, et al.
Publicado: (2012)

Weight loss for reduction of proteinuria in diabetic nephropathy: Comparison with angiotensin-converting enzyme inhibitor therapy
por: Patil, M. R., et al.
Publicado: (2013)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis
por: Gundlach, Enken, et al.
Publicado: (2016)

Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model
por: Adarkwah, Charles Christian, et al.
Publicado: (2011)

Polymorphism of Angiotensin-Converting Enzyme (rs4340) and Diabetic Nephropathy in Caucasians with Type 2 Diabetes Mellitus
por: Šeruga, M, et al.
Publicado: (2016)

Targeting c-fms kinase attenuates chronic aristolochic acid nephropathy in mice
por: Dai, Xiao Y., et al.
Publicado: (2016)

Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy
por: Wu, Minmin, et al.
Publicado: (2020)

Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy
por: Ishii, Takeo, et al.
Publicado: (2021)

Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review
por: Huang, Yunyu, et al.
Publicado: (2014)

Combination therapy with an angiotensin‐converting‐enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy
por: Nakamura, Akihiko, et al.
Publicado: (2012)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gobe7gi584l2ljefk2fa4u4sjr